1
|
Dusek J, Mejdrová I, Dohnalová K, Smutny T, Chalupsky K, Krutakova M, Skoda J, Rashidian A, Pavkova I, Škach K, Hricová J, Chocholouskova M, Smutna L, Kamaraj R, Hroch M, Leníček M, Mičuda S, Pijnenburg D, van Beuningen R, Holčapek M, Vítek L, Ingelman-Sundberg M, Burk O, Kronenberger T, Nencka R, Pavek P. The hypolipidemic effect of MI-883, the combined CAR agonist/ PXR antagonist, in diet-induced hypercholesterolemia model. Nat Commun 2025; 16:1418. [PMID: 39915454 PMCID: PMC11802874 DOI: 10.1038/s41467-025-56642-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2024] [Accepted: 01/20/2025] [Indexed: 02/09/2025] Open
Abstract
Constitutive androstane receptor (CAR) and pregnane X receptor (PXR) are closely related nuclear receptors with overlapping regulatory functions in xenobiotic clearance but distinct roles in endobiotic metabolism. Car activation has been demonstrated to ameliorate hypercholesterolemia by regulating cholesterol metabolism and bile acid elimination, whereas PXR activation is associated with hypercholesterolemia and liver steatosis. Here we show a human CAR agonist/PXR antagonist, MI-883, which effectively regulates genes related to xenobiotic metabolism and cholesterol/bile acid homeostasis by leveraging CAR and PXR interactions in gene regulation. Through comprehensive analyses utilizing lipidomics, bile acid metabolomics, and transcriptomics in humanized PXR-CAR-CYP3A4/3A7 mice fed high-fat and high-cholesterol diets, we demonstrate that MI-883 significantly reduces plasma cholesterol levels and enhances fecal bile acid excretion. This work paves the way for the development of ligands targeting multiple xenobiotic nuclear receptors. Such ligands hold the potential for precise modulation of liver metabolism, offering new therapeutic strategies for metabolic disorders.
Collapse
Affiliation(s)
- Jan Dusek
- Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Ivana Mejdrová
- Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic
| | - Klára Dohnalová
- Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
- First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Tomas Smutny
- Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Karel Chalupsky
- Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
| | - Maria Krutakova
- Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Josef Skoda
- Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Azam Rashidian
- Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tübingen Center for Academic Drug Discovery, Eberhard Karls University Tübingen, Tübingen, Germany
| | - Ivona Pavkova
- Military Faculty of Medicine, University of Defence, Hradec Králové, Czech Republic
| | - Kryštof Škach
- Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic
| | - Jana Hricová
- Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic
| | - Michaela Chocholouskova
- Department of Analytical Chemistry, University of Pardubice, Faculty of Chemical Technology, Pardubice, Czech Republic
| | - Lucie Smutna
- Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Rajamanikkam Kamaraj
- Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Miloš Hroch
- Department of Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | - Martin Leníček
- Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Stanislav Mičuda
- Institute of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czech Republic
| | | | | | - Michal Holčapek
- Department of Analytical Chemistry, University of Pardubice, Faculty of Chemical Technology, Pardubice, Czech Republic
| | - Libor Vítek
- Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 4th Department of Internal Medicine, General University Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Magnus Ingelman-Sundberg
- Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
| | - Oliver Burk
- Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tuebingen, Tuebingen, Germany
| | - Thales Kronenberger
- Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tübingen Center for Academic Drug Discovery, Eberhard Karls University Tübingen, Tübingen, Germany
- School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland
| | - Radim Nencka
- Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
| | - Petr Pavek
- Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
| |
Collapse
|
2
|
Mukai Y, Yamaguchi A, Sakuma T, Nadai T, Furugen A, Narumi K, Kobayashi M. Involvement of
SLC16A1
/MCT1 and
SLC16A3
/MCT4 in
l
‐lactate transport in the hepatocellular carcinoma cell line. Biopharm Drug Dispos 2022; 43:183-191. [DOI: 10.1002/bdd.2329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Revised: 09/05/2022] [Accepted: 09/06/2022] [Indexed: 11/10/2022]
Affiliation(s)
- Yuto Mukai
- Laboratory of Clinical Pharmaceutics & Therapeutics Division of Pharmasciences Faculty of Pharmaceutical Sciences Hokkaido University Kita‐12‐jo, Nishi‐6‐chome, Kita‐ku Sapporo 060‐0812 Japan
| | - Atsushi Yamaguchi
- Department of Pharmacy Hokkaido University Hospital Kita‐14‐jo, Nishi ‐5‐chome, Kita‐ku Sapporo 060‐8648 Japan
| | - Tomoya Sakuma
- Laboratory of Clinical Pharmaceutics & Therapeutics Division of Pharmasciences Faculty of Pharmaceutical Sciences Hokkaido University Kita‐12‐jo, Nishi‐6‐chome, Kita‐ku Sapporo 060‐0812 Japan
| | - Takanobu Nadai
- Laboratory of Clinical Pharmaceutics & Therapeutics Division of Pharmasciences Faculty of Pharmaceutical Sciences Hokkaido University Kita‐12‐jo, Nishi‐6‐chome, Kita‐ku Sapporo 060‐0812 Japan
| | - Ayako Furugen
- Laboratory of Clinical Pharmaceutics & Therapeutics Division of Pharmasciences Faculty of Pharmaceutical Sciences Hokkaido University Kita‐12‐jo, Nishi‐6‐chome, Kita‐ku Sapporo 060‐0812 Japan
| | - Katsuya Narumi
- Laboratory of Clinical Pharmaceutics & Therapeutics Division of Pharmasciences Faculty of Pharmaceutical Sciences Hokkaido University Kita‐12‐jo, Nishi‐6‐chome, Kita‐ku Sapporo 060‐0812 Japan
| | - Masaki Kobayashi
- Laboratory of Clinical Pharmaceutics & Therapeutics Division of Pharmasciences Faculty of Pharmaceutical Sciences Hokkaido University Kita‐12‐jo, Nishi‐6‐chome, Kita‐ku Sapporo 060‐0812 Japan
| |
Collapse
|
3
|
Luo Y, Lu H, Peng D, Ruan X, Chen YE, Guo Y. Liver-humanized mice: A translational strategy to study metabolic disorders. J Cell Physiol 2022; 237:489-506. [PMID: 34661916 PMCID: PMC9126562 DOI: 10.1002/jcp.30610] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Revised: 09/07/2021] [Accepted: 09/11/2021] [Indexed: 01/03/2023]
Abstract
The liver is the metabolic core of the whole body. Tools commonly used to study the human liver metabolism include hepatocyte cell lines, primary human hepatocytes, and pluripotent stem cells-derived hepatocytes in vitro, and liver genetically humanized mouse model in vivo. However, none of these systems can mimic the human liver in physiological and pathological states satisfactorily. Liver-humanized mice, which are established by reconstituting mouse liver with human hepatocytes, have emerged as an attractive animal model to study drug metabolism and evaluate the therapeutic effect in "human liver" in vivo because the humanized livers greatly replicate enzymatic features of human hepatocytes. The application of liver-humanized mice in studying metabolic disorders is relatively less common due to the largely uncertain replication of metabolic profiles compared to humans. Here, we summarize the metabolic characteristics and current application of liver-humanized mouse models in metabolic disorders that have been reported in the literature, trying to evaluate the pros and cons of using liver-humanized mice as novel mouse models to study metabolic disorders.
Collapse
Affiliation(s)
- Yonghong Luo
- Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA
- Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
| | - Haocheng Lu
- Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA
| | - Daoquan Peng
- Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
| | - Xiangbo Ruan
- Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins School of Medicine, Johns Hopkins All Children’s Hospital, St. Petersburg, FL 33701, USA
| | - Y. Eugene Chen
- Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA
- Center for Advanced Models and Translational Sciences and Therapeutics, University of Michigan, Ann Arbor, MI 48109, USA
| | - Yanhong Guo
- Department of Internal Medicine, Cardiovascular Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA
| |
Collapse
|
4
|
Holgersen EM, Gandhi S, Zhou Y, Kim J, Vaz B, Bogojeski J, Bugno M, Shalev Z, Cheung-Ong K, Gonçalves J, O'Hara M, Kron K, Verby M, Sun M, Kakaradov B, Delong A, Merico D, Deshwar AG. Transcriptome-Wide Off-Target Effects of Steric-Blocking Oligonucleotides. Nucleic Acid Ther 2021; 31:392-403. [PMID: 34388351 PMCID: PMC8713556 DOI: 10.1089/nat.2020.0921] [Citation(s) in RCA: 47] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Accepted: 07/06/2021] [Indexed: 11/29/2022] Open
Abstract
Steric-blocking oligonucleotides (SBOs) are short, single-stranded nucleic acids designed to modulate gene expression by binding to RNA transcripts and blocking access from cellular machinery such as splicing factors. SBOs have the potential to bind to near-complementary sites in the transcriptome, causing off-target effects. In this study, we used RNA-seq to evaluate the off-target differential splicing events of 81 SBOs and differential expression events of 46 SBOs. Our results suggest that differential splicing events are predominantly hybridization driven, whereas differential expression events are more common and driven by other mechanisms (including spurious experimental variation). We further evaluated the performance of in silico screens for off-target splicing events, and found an edit distance cutoff of three to result in a sensitivity of 14% and false discovery rate (FDR) of 99%. A machine learning model incorporating splicing predictions substantially improved the ability to prioritize low edit distance hits, increasing sensitivity from 4% to 26% at a fixed FDR of 90%. Despite these large improvements in performance, this approach does not detect the majority of events at an FDR <99%. Our results suggest that in silico methods are currently of limited use for predicting the off-target effects of SBOs, and experimental screening by RNA-seq should be the preferred approach.
Collapse
Affiliation(s)
- Erle M. Holgersen
- Deep Genomics, Inc., Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Shreshth Gandhi
- Deep Genomics, Inc., Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Yongchao Zhou
- Deep Genomics, Inc., Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Jinkuk Kim
- Deep Genomics, Inc., Toronto,
Canada
- Graduate School of Medical Science and
Engineering, KAIST, Daejeon, Republic of Korea
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Brandon Vaz
- Deep Genomics, Inc., Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Jovanka Bogojeski
- Deep Genomics, Inc., Toronto,
Canada
- Providence Therapeutics, Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Magdalena Bugno
- Deep Genomics, Inc., Toronto,
Canada
- The Hospital for Sick Children, Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Zvi Shalev
- Deep Genomics, Inc., Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Kahlin Cheung-Ong
- Deep Genomics, Inc., Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - João Gonçalves
- Deep Genomics, Inc., Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Matthew O'Hara
- Deep Genomics, Inc., Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Ken Kron
- Deep Genomics, Inc., Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Marta Verby
- Deep Genomics, Inc., Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Mark Sun
- Deep Genomics, Inc., Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Boyko Kakaradov
- Deep Genomics, Inc., Toronto,
Canada
- Skyhawk Therapeutics, Waltham,
Massachusetts, USA
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Andrew Delong
- Deep Genomics, Inc., Toronto,
Canada
- Department of Computer Science and
Software Engineering, Concordia University, Montreal, Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Daniele Merico
- Deep Genomics, Inc., Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| | - Amit G. Deshwar
- Deep Genomics, Inc., Toronto,
Canada
- This article was previously published in bioRxiv, Preprint DOI: https://doi.org/10.1101/2020.09.03.281667
| |
Collapse
|